Clarifying the Role of the Mantel-Haenszel Risk Difference Estimator in Randomized Clinical Trials

Yuhan Qian Co-Author
University of Washington
 
Jaehwan Yi Co-Author
Pennsylvania State University
 
Jinqiu Wang Co-Author
 
Yu Du Co-Author
Eli Lilly and Company
 
Yanyao Yi Co-Author
Eli Lilly and Company
 
Ting Ye Co-Author
University of Washington
 
Xiaoyu Qiu First Author
 
Xiaoyu Qiu Presenting Author
 
Thursday, Aug 7: 8:50 AM - 9:05 AM
1497 
Contributed Papers 
Music City Center 
The Mantel-Haenszel (MH) risk difference estimator is widely used for binary outcomes in randomized clinical trials. This estimator computes a weighted average of stratum-specific risk differences and traditionally requires the stringent assumption of homogeneous risk difference across strata. In our study, we relax this assumption and demonstrate that the MH risk difference estimator consistently estimates the average treatment effect. Furthermore, we rigorously study its properties under two asymptotic frameworks: one characterized by a small number of large strata and the other by a large number of small strata. Additionally, a unified robust variance estimator that improves over the popular Greenland's and Sato's variance estimators is proposed, and we prove that it is applicable across both asymptotic scenarios. Our findings are validated through simulations and real data applications.

Keywords

Average treatment effect

Covariate adjustment

Robust variance estimation

Stratified 2 × 2 table

Difference of proportion 

Main Sponsor

Biometrics Section